Loading
VI
Vapotherm Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Army Joseph, was filed 11 Sept 2023.
Vapotherm Inc: what insiders have been doing
Every trade that managers of Vapotherm Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Stevensville, United States. It was founded in 1999. No insider at Vapotherm Inc has published a filing in the past twelve months. The most recent one dates from 24 September 2024.
Our records for Vapotherm Inc go back to 2018, with 77 purchases and 69 sales on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
413
Thresholds
n/a
Buy Volume
€23M
77 ops. · all time
Sell Volume
€6M
69 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$59.1M
Gross profitUS$24.4M41% margin
Net income-US$50.1M-84.7% margin
Last declaration on 24 September 2024
Declarations413 total
1,693 sharesCommon StockSEC:0001235802-24-000082:2
425 sharesCommon StockSEC:0001235802-24-000082:3
187 sharesCommon StockSEC:0001235802-24-000082:4
50,308 shares@ US$2.189.5% of flowCommon StockSEC:0001235802-24-000079:1
4,500 shares@ US$2.180.9% of flowCommon StockSEC:0001235802-24-000079:2
16,746 shares@ US$2.1863.7% of flowCommon StockSEC:0001235802-24-000080:1
3,000 shares@ US$2.182.6% of flowCommon StockSEC:0001235802-24-000074:1
2,500 shares@ US$2.183.6% of flowCommon StockSEC:0001235802-24-000076:1
2,375 shares@ US$2.185.3% of flowCommon StockSEC:0001235802-24-000077:1
37,319 shares@ US$2.1833.9% of flowCommon StockSEC:0001235802-24-000081:1
3,000 shares@ US$2.180.3% of flowCommon StockSEC:0001235802-24-000078:1
81,546 shares@ US$2.187.3% of flowCommon StockSEC:0001235802-24-000078:2
23,845 shares@ US$2.186.1% of flowCommon StockSEC:0001235802-24-000082:1
22,869 sharesCommon StockSEC:0001235802-24-000081:0
7,862 shares@ US$2.1818.7% of flowCommon StockSEC:0001235802-24-000077:0
8,352 shares@ US$2.1812.5% of flowCommon StockSEC:0001235802-24-000076:0
9,696 shares@ US$2.1811.9% of flowCommon StockSEC:0001235802-24-000074:0
17,500 shares@ US$0.91183.1% of flowCommon StockSEC:0001235802-24-000079:0
22,485 shares@ US$2.1815.9% of flowCommon StockSEC:0001235802-24-000075:0
14,555 shares@ US$2.183.7% of flowCommon StockSEC:0001235802-24-000078:0
19,917 shares@ US$2.182.7% of flowCommon StockSEC:0001235802-24-000083:1
2,625 shares@ US$2.180.8% of flowCommon StockSEC:0001235802-24-000084:1
6,112 shares@ US$2.181.8% of flowCommon StockSEC:0001235802-24-000084:3
149,201 shares@ US$2.1845.0% of flowCommon StockSEC:0001235802-24-000084:4
3,000 shares@ US$2.182.1% of flowCommon StockSEC:0001235802-24-000075:1
25 of 413 declarations
About Vapotherm Inc
Vapotherm Inc. is a U.S.-based medical device company listed on the American market NYSE/NASDAQ and headquartered in Exeter, New Hampshire, United States. The company focuses on advanced respiratory support technologies, with a core positioning around patient comfort and non-invasive treatment for acute and chronic breathing disorders. Founded in 1993 and later reincorporated in Delaware in 2013, Vapotherm built its franchise as a niche respiratory-therapy specialist rather than a broad multi-platform medtech group.
From an operating standpoint, Vapotherm’s business centers on high-velocity therapy systems, related consumables, and accessories, along with adjacent respiratory-support solutions. Its products are primarily used in hospitals, emergency departments, intensive care settings, and other acute-care environments where ease of use, rapid deployment, and patient tolerance matter. The company’s portfolio includes its next-generation HVT platform and associated device ecosystem designed to support clinicians treating patients with respiratory distress while offering an alternative to more invasive forms of ventilation.
Read moreShow less
Competitively, Vapotherm is best viewed as a specialized player. Its differentiation comes from product focus, clinical workflow integration, and adoption within acute-care institutions, rather than from scale or breadth of portfolio. That niche positioning can be attractive in segments where hospitals want non-invasive respiratory options and differentiated therapy outcomes, but it also means the company is sensitive to hospital purchasing cycles, reimbursement dynamics, regulatory execution, and the pace of commercial adoption. In this sense, Vapotherm’s market position is more about targeted clinical utility than mass-market volume.
Geographically, the company is anchored in the United States, with its principal executive offices in Exeter, New Hampshire, and it has also referenced a U.K. reporting unit in its SEC filings. This suggests a commercial footprint that extends beyond the U.S., although the domestic market remains its main reference point. Recent developments have been important. In December 2025, Vapotherm announced a strategic partnership with Flight Medical Innovations to bring the VentO2ux ventilator to U.S. hospitals, broadening its portfolio beyond high-velocity therapy devices into a more complete respiratory-support offering. In 2024, Vapotherm also pursued a strategic transaction that resulted in acquisition by an affiliate-linked vehicle associated with Perceptive Advisors, a major corporate event that remains highly relevant for investors assessing the company’s equity story and future operating profile.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
